cancer/testis antigen family 45 member A3Genealiases: CT45-3 · CT45-4 · CT45.3 · CT45.4 · CT45A4
Q-omics provides the consensus-scored CT45A3 profile across patient tissues and cancer cell-line models. CT45A3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CT45A3 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, CT45A3 RNA expression shows 9,565 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where CT45A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT45A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT45A3 survival associations across molecular data types. CT45A3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT45A3 RNA expression–survival associations across cancer types. High CT45A3 expression shows unfavorable associations in COAD, KIRC, STAD, SCLC and UCEC, but favorable associations in OV. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CT45A3 RNA expression.
This table summarizes CT45A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CT45A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT45A3 shows higher tumor expression in HNSC, LUSC and KIRC. The HNSC box plot shows higher CT45A3 RNA expression in tumor versus normal tissue (log2 FC = +0.147, t-test p = .019).
This table shows molecular features associated with CT45A3 in patient tissues and cancer cell lines. In patient samples, CT45A3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CT45A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
